Abstract
Opioid-induced constipation (OIC) is common and can significantly affect quality of life. Naloxegol and methylnaltrexone are peripherally acting µ-opioid receptor antagonists (PAMORAs) which are effective for the management of OIC. We report on a case in the palliative care setting where a patient with established OIC had an inadequate response to naloxegol but an effective and immediate response to methylnaltrexone at the dose recommended for her weight. This is the first reported case of two PAMORAs used concomitantly.
Subject
Medical–Surgical,Oncology(nursing),General Medicine,Medicine (miscellaneous)
Reference5 articles.
1. Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
2. National Institute for Health and Care Excellence (NICE) . Naloxegol for treating opioid-induced constipation. Technology appraisal guidance [TA345], 2015. Available: https://www.nice.org.uk/guidance/ta345/chapter/4-Consideration-of-the-evidence [Accessed 25 Apr 2019].
3. Naloxegol
4. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients
5. Summary of Product Characteristics . Moventig® 12.5mg and 25Mg tablets. Available: https://www.medicines.org.uk/emc/product/6892/smpc [Accessed 30 Apr 2019].
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Opioid analgesics;Reactions Weekly;2021-01